New pill aims to wipe out rare bladder tumors without surgery

NCT ID NCT07265947

Recruiting now Disease control Sponsor: Tyra Biosciences, Inc Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 22 times

Summary

This study tests a new oral drug, dabogratinib, in 230 adults with a rare, low-grade cancer of the upper urinary tract. The goal is to see if the drug can make tumors disappear completely within six months. Participants must have a specific genetic marker (FGFR3) and a visible tumor left behind for measurement.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44111, United States
Duly Health and Care Chicago
RECRUITING

Lisle, Illinois, 60532, United States
First Urology
RECRUITING

Jeffersonville, Indiana, 47130, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Urology Associates, P C
RECRUITING

Nashville, Tennessee, 37209-4035, United States

Conditions

Explore the condition pages connected to this study.

LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA